Prana Provides Huntington Disease Trial Update

[at noodls] – in conjunction with the Huntington Study Group Annual Conference Melbourne – 14 November, 2012; Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today reported on its progress in the Reach2HD trial, following … more

View todays social media effects on PRAN

View the latest stocks trending across Twitter. Click to view dashboard